发明名称 |
Engineered antibody-interferon mutant fusion molecules |
摘要 |
The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (TAA) antibody (Ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell. In various embodiments, the engineered fusion molecules comprise a TAA Ab fused to an interferon-alpha (IFN-α) mutant molecule. The engineered Ab-IFN-α mutant fusion molecules of the present invention demonstrate improved therapeutic index and preserved or increased efficacy as compared to Ab-wildtype IFN-α fusion molecules, and/or demonstrate improved PK properties as compared to Ab-wildtype IFN-α fusion molecules. |
申请公布号 |
US8980267(B2) |
申请公布日期 |
2015.03.17 |
申请号 |
US201313784049 |
申请日期 |
2013.03.04 |
申请人 |
ImmunGene Inc |
发明人 |
Grewal Iqbal;Khare Sanjay;Gresser Michael;Syed Rashid |
分类号 |
A61K39/00;A61K39/395;A61K38/21;A61K38/00;C07K14/56;C07K16/46;C07K16/30;C07K16/00;C12P21/08;C07K16/18;C07K16/28;C07K16/32 |
主分类号 |
A61K39/00 |
代理机构 |
Craig A Crandall, APC |
代理人 |
Craig A Crandall, APC |
主权项 |
1. A genetically engineered fusion molecule comprising a tumor-associated antigen (TAA) antibody (Ab) attached to an interferon alpha (IFN-α) mutant molecule, wherein said antibody is attached directly to said IFN-α mutant molecule, wherein said IFN-α mutant molecule is a mutated human IFN-α2 molecule comprising at least one mutation in SEQ ID NO: 13, wherein said mutation is selected from H57A, E58A, L30A, and F27A, and wherein the TAA antibody is an IgG antibody. |
地址 |
Camarillo CA US |